# Sernova Sernova is an other based in London, Canada. ## Overview - **Organization type:** other - **Headquarters:** London, Canada - **Region:** North America - **Address:** London, ON, Canada - **Founded:** 2000 - **Assets under management:** Undisclosed - **Website:** sernova.com ## Regulatory record - **Reports private funds:** No ## About Sernova was founded in 2000 and operates from London, Ontario, as a clinical-stage regenerative medicine company. The firm is not an asset manager or family office; it is an operating biotechnology company focused on commercializing a proprietary, implantable medical device. Its core technology, the Cell Pouch System, is a surgically implanted, closeable device that forms a natural vascularized tissue environment, designed to house therapeutic cells that can then produce proteins or hormones the patient's own body is unable to make in sufficient quantity. The lead program targets type 1 diabetes by loading the Cell Pouch with donor-derived insulin-producing islet cells. Sernova also runs a separate program for hypothyroidism. In 2022, Sernova entered a strategic collaboration with AstraZeneca to evaluate novel therapeutic cells in the Cell Pouch, an indication that extends the platform's potential beyond the initial endocrine disorders (per the firm, 2022). The primary clinical trial for the diabetes program is a Phase I/II study at sites in the United States and Canada, examining safety, efficacy, and long-term islet survival. The company is listed on the Toronto Stock Exchange and trades over-the-counter in the United States. Cynthia Pussinen took over as CEO in December 2021, bringing extensive cell and gene therapy commercial experience from previous roles at Akcea Therapeutics, Spark Therapeutics, and Novartis (per Sernova, December 2021). The firm does not currently hold any approved revenue-generating products, funding operations entirely through equity offerings, research grants, and strategic partnership payments. Its fundraising history includes multiple public and private placements, the most recent being a C$4 million direct offering in January 2024 to fund ongoing clinical operations. Sernova's structure distinguishes it from a traditional biotech bet on a single molecule. The Cell Pouch is a drug-agnostic delivery platform, meaning its commercial fate is not tied to one therapeutic cell type but to the system's ability to work with a range of cell therapies. This creates a licensing and partnership flywheel potential that is unusual for a company of its sub-C$200 million market capitalization. However, the path to an approved product requires proving long-term viability and function of transplanted cells without chronic immunosuppression, a challenge that remains the company's primary existential risk. ## Sectors - Digital Health ## People - Cynthia Pussinen — Chief Executive Officer ## Questions ### What does Sernova's Cell Pouch actually do? The Cell Pouch is a small, implantable, closeable device that is surgically placed under the skin. Over several weeks, the body grows a natural, vascularized tissue chamber around and within the device. Once mature, therapeutic cells — such as insulin-producing islets for diabetes — are inserted into the chamber, where they can engraft and function long-term, essentially creating an organ-like environment within the body. ### How is Sernova funded if it has no approved product? Sernova does not generate product revenue. Its operations are funded through periodic equity offerings on the Toronto Stock Exchange, strategic partnership payments, and research grants. Its most recent raise was a C$4 million direct offering in January 2024. The firm has sustained R&D operations for over two decades under this model, relying on long-duration public market and strategic investor support. ### What is Sernova's lead clinical-stage program? The lead program is a Phase I/II clinical trial for type 1 diabetes. It tests the Cell Pouch loaded with human donor islets, transplanted into patients with severe, unstable type 1 diabetes. The study measures safety and efficacy endpoints including insulin independence and sustained C-peptide levels as markers of functioning islets. ### What is the biggest clinical risk facing Sernova's technology? The central risk is the requirement for chronic immunosuppression to prevent rejection of the donor islet cells. Currently, patients in the trial must take standard immunosuppressive drugs, which carry significant long-term health risks. The ultimate commercial viability of the platform is often linked to progress on immune-protected cell technologies or the firm's own efforts to induce immune tolerance, which remain unproven. ## Related profiles - [Jerash Holdings](https://altss.com/profile/jerash-holdings-us-inc) --- Last updated: 2026-06-03T20:00:00.000Z Canonical page: https://altss.com/profile/sernova-corp Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology